Genomenon Provides Genomic Data on 450 Diseases to Advance Early Identification of Rare Disease in Newborns
ANN ARBOR, Mich., Nov. 15, 2022 /PRNewswire-PRWeb/ -- Genomenon, Inc., an AI-driven genomics company, announced more details on their plan to curate the genes associated with over 450 rare diseases for the purpose of newborn screening via next generation DNA sequencing. The program is the first initiative in Genomenon's mission to curate the entire human genome and is an essential part of the BeginNGS™ newborn sequencing project led by Rady Children's Institute for Genomic Medicine (RCIGM).
- When identified early, many rare diseases can be treated preemptively to head-off disastrous consequences of later stage diagnosis.
- Genomenon's goal is to expand the knowledgebase to cover all 7,000 rare diseases and make the data available to labs and testing centers wishing to expand their rare disease testing.
- "We've been working with Genomenon since the very early creation of the Mastermind Genomic Search Engine," said A/Prof.
- Genomenon is an AI-driven genomics company focused on making genomic information actionable for patients with rare genetic diseases and cancer.